804 related articles for article (PubMed ID: 16423493)
1. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
2. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
[TBL] [Abstract][Full Text] [Related]
3. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman M; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
7. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
Davies TA; Yee YC; Goldschmidt R; Sahm DF; Evangelista AT
Postgrad Med; 2008 Sep; 120(3 Suppl 1):39-45. PubMed ID: 18931470
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).
Davies TA; Goldschmidt R; Pfleger S; Loeloff M; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2003 Aug; 52(2):168-75. PubMed ID: 12837740
[TBL] [Abstract][Full Text] [Related]
9. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
[TBL] [Abstract][Full Text] [Related]
10. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.
Johnson AP; Sheppard CL; Harnett SJ; Birtles A; Harrison TG; Brenwald NP; Gill MJ; Walker RA; Livermore DM; George RC
J Antimicrob Chemother; 2003 Dec; 52(6):953-60. PubMed ID: 14585858
[TBL] [Abstract][Full Text] [Related]
11. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
12. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
Johnson DM; Stilwell MG; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
[TBL] [Abstract][Full Text] [Related]
13. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Fedler KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
[TBL] [Abstract][Full Text] [Related]
14. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.
Richter SS; Heilmann KP; Dohrn CL; Riahi F; Beekmann SE; Doern GV
Clin Infect Dis; 2009 Feb; 48(3):e23-33. PubMed ID: 19115971
[TBL] [Abstract][Full Text] [Related]
15. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Adam HJ; Schurek KN; Nichol KA; Hoban CJ; Baudry TJ; Laing NM; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2007 Jan; 51(1):198-207. PubMed ID: 17088485
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
[TBL] [Abstract][Full Text] [Related]
20. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
